By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics on Wednesday said that it will likely have to reschedule its shareholders' meeting to vote on the acquisition RedRath Integrated Pathology.

The meeting is scheduled for June 28, but ExonHit said that it expects that there will be a lack of quorum to vote on the matter. In that case, the meeting will be rescheduled for July 8. A final decision on when the meeting will take place will be made on June 28, according to an ExonHit spokesperson.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.